Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020118109 - MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF

Publication Number WO/2020/118109
Publication Date 11.06.2020
International Application No. PCT/US2019/064779
International Filing Date 05.12.2019
IPC
A61K 38/05 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
05Dipeptides
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/73
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applicants
  • CYTOMX THERAPEUTICS, INC. [US]/[US]
Inventors
  • VASILJEVA, Olga
  • WINTER, Michael B.
Agents
  • SHIN, Tae Bum
Priority Data
62/776,40906.12.2018US
62/778,06211.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
(FR) SUBSTRATS CLIVABLES PAR MÉTALLOPROTÉASE MATRICIELLE ET CLIVABLES PAR SÉRINE OU CYSTÉINE PROTÉASE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
Abstract
(EN)
The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP) or at least one cysteine protease (CP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP), and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP) in a variety of therapeutic, diagnostic and prophylactic indications.
(FR)
La présente invention concerne généralement des polypeptides qui comprennent au moins un premier fragment clivable (CM1) qui est un substrat pour au moins une métalloprotéase matricielle (MMP) et au moins un deuxième fragment clivable (CM2) qui est un substrat pour au moins une sérine protéase (SP) ou au moins une cystéine protéase (CP), des anticorps activables et d'autres molécules plus grandes qui comprennent ces polypeptides qui incluent au moins un CM1 qui est un substrat pour au moins une protéase MMP et au moins un CM2 qui est un substrat pour au moins une protéase SP ou au moins une cystéine protéase (CP), et des procédés de fabrication et d'utilisation de ces polypeptides qui comprennent au moins un CM1 qui est un substrat pour au moins une protéase MMP et au moins un CM2 qui est un substrat pour au moins une protéase SP ou au moins une cystéine protéase (CP) dans différentes indications thérapeutiques, diagnostiques et prophylactiques.
Latest bibliographic data on file with the International Bureau